2026

ATC抗體藥物暨第21屆前瞻生醫新知研討會

Antibody Therapeutic Conference & 21st Frontiers in Biomedical Sciences Conference

Date 26(Tue.) - 27(Wed.), May, 2026

Location C201 International Conference Hall,
National Biotechnology Research Park (NBRP)

Welcome Message

Dear distinguished guests, ladies and gentlemen,

On behalf of the organizing committee, it is my great pleasure to welcome you to the Antibody Therapeutic Conference (ATC) - the 2026 Antibody Therapeutics Conference: Extended Applications of Antibodies. The conference will be held on May 26-27, 2026, at the National Biotechnology Research Park in Taipei, Taiwan.

In recent years, the field of antibody therapeutics has continued to experience remarkable growth, particularly in the treatment of cancer, immune-mediated diseases, and infectious diseases. Advances in antibody engineering have led to the rapid development of next-generation modalities, including bispecific antibodies, antibody-drug conjugates (ADCs), and T-cell-engaging therapies.

These innovative immunotherapies-ranging from checkpoint blockade and ADCs to chimeric antigen receptor T-cell (CAR-T) therapies-are transforming the landscape of modern medicine and offering new hope for patients with previously difficult-to-treat diseases.

This year, ATC will continue to showcase a broad spectrum of remarkable achievements, with a focus on the extended applications of antibodies and emerging therapeutic modalities for the treatment of human diseases. We aim to provide a platform for participants to connect, communicate, gain new knowledge, and discuss the latest advances in this rapidly evolving field.

The Taiwan Antibody Association (TAA), the organizer of ATC, was established in 2012 with the mission of facilitating research and industrial development of antibody therapeutics and related technologies in Taiwan. By hosting international conferences such as ATC, we hope to promote the exchange of ideas and foster collaborations between senior experts and young scientists from around the world.

We sincerely hope that this conference will be informative and inspiring, and that it will encourage meaningful contributions to the advancement of antibody therapeutics. Once again, we thank you for joining us and wish you a productive and enjoyable conference.

Han-Chung Wu, Ph.D.

Chairman, Taiwan Antibody Association

Distinguished Research Fellow, Institute of Cellular and Organismic Biology, Academia Sinica

Fellow, National Academy of Inventors (NAI)

Contents

Agenda

Date: 26(Tue.), May, 2026

Time	Agenda
08:30 - 09:00	**Registration**
09:00 - 09:10	Welcome Remarks **Han-Chung Wu 吳漢忠** Chairman of Taiwan Antibody Association; Distinguished Research Fellow, Institute of Cellular and Organismic Biology, Academia Sinica
09:10 - 09:15	Moderator **John Yu 游正博** Distinguished Research Fellow, Institute of Stem Cell & Translational Cancer Research, CGMH Institute of Cellular and Organismic Biology, Academia Sinica
09:15 - 10:05	**Keynote:《Architecting the Lead: Antibody Development for Clinical Success in the AI Era》** **Man-Cheong Fung** President, Macafex Consulting LLC, USA
10:05 - 10:25	**Break**
10:25 - 10:30	Moderator **Dah-Tsyr Chang 張大慈** CSO, Jellox Biotech Inc.
10:30 - 11:20	**Keynote:《Single nanoparticle biology for nucleic acid-based vaccine and adjuvant》** **Ken J. Ishii 石井健** Professor and Director, Vaccine Science Division, Institute of Medical Science,The University of Tokyo
11:20 - 11:55	**《CD33 blockade restores coordinated antiviral immunity and accelerates HBsAg clearance in chronic hepatitis B》** **Shie-Liang Hsieh 謝世良** Distinguished Investigator and Director, Immunology Research Center, National Health Research Institutes
11:55 - 12:00	5th TAA General Assembly
12:00 - 13:30	**Lunch Seminar 3F** **Unimed Healthcare / Sartorius / Omics Biotechnology /ABreal Biotech / Gator Bio**
13:30 - 13:35	Moderator **Andrew H.-J. Wang 王惠鈞** Academician, Academia Sinica
13:35 - 14:25	**Keynote：《Chasing the Promise of Cancer Immunotherapy》** **Alice L. Yu 陳鈴津** Distinguished Chair Professor, Institute of Stem Cell & Translational Cancer Research in Chang Gung Memorial Hospital / Academician, Academia Sinica
14:25 - 15:00	**《Targeting ER Protein TXNDC5 to Mitigate Organ Fibrosis and Tumor Desmoplasia》** **Kai-Chien Yang 楊鎧鍵** Chair and Distinguished Professor, Graduate Institute and Department of Pharmacology, National Taiwan University
15:00 - 15:30	**Break**
15:30 - 15:35	Moderator **Sherry, Mann-Ching Ku 顧曼芹** Founder & General Manager, Kuder Consulting Inc.
15:35 - 16:10	**《Modernizing Cell Line Development: Data-Driven Strategies for Biopharmaceutical Success》** **Divay Bagga** Global Product Excellence Manager, Cell Line Development (CLD), Sartorius
16:10 - 16:45	**《Next-Generation mAb Therapeutics: Insights from a CDMO Perspective》** **Pei-Jiun Chen 陳佩君** CEO & President, Mycenax Biotech
16:45 - 16:50	**Closing Remarks**

Date: 27(Wed.), May, 2026

Time	Agenda
08:30 - 09:00	**Registration**
09:00 - 09:05	Welcome Remarks **Jung-Yaw Lin 林榮耀** Chairman, Jung-Yaw Lin Science and Education Foundation **Han-Chung Wu 吳漢忠** CEO, Jung-Yaw Lin Science and Education Foundation
09:05 - 09:10	Moderator **Yan-Hwa Wu Lee 吳妍華** Academician, Academia Sinica
09:10 - 09:45	**《Long-term Risk Calculators of Liver Cancer and Cirrhosis in Taiwan: Precision Liver Disease Prevention through Molecular and Genomic Epidemiological Studies》** **Chien-Jen Chen 陳建仁** Academician/Distinguished Research Fellow, Genomics Research Center, Academia Sinica
09:45 - 10:20	**《Unraveling the biological processes of pancreatic ductal adenocarcinoma initiation and metastasis》** **Wen-Hwa Lee 李文華** Academician/Visiting Distinguished Chair Research Fellow, Academia Sinica
10:20 - 10:50	**Break**
10:50 - 10:55	Moderator **Yau-Huei Wei 魏耀揮** Director, Center for Mitochondrial Medicine and Free Radical Research, Changhua Christian Hospital (CCH)
10:55 - 11:30	**《EV-mRNAs as Biomarkers and Mediators of Sarcopenia and Muscle Aging》** **Hsing-Jien Kung 龔行健** Chair Professor, Taipei Medical University, Taiwan
11:30 - 12:05	**《Plant cells as bioreactors for production of therapeutic proteins with humanized posttranslational modification patterns》** **Ming-Che Shih 施明哲** Academician, Academia Sinica
12:05 - 12:10	**Closing Remarks**
12:10 - 13:30	**餐敘與慶生 Lunch (Invitation only)**
14:00 - 16:00	Workshop (Requires Separate Registration) **《Transcending Limits: The Convergence of Frontier Biomedical Innovations》** **Man-Cheong Fung** President, Macafex Consulting LLC, USA

Moderator

John Yu 游正博

Distinguished Research Fellow, Institute of Stem Cell & Translational Cancer Research, CGMH
Institute of Cellular and Organismic Biology, Academia Sinica

Dah-Tsyr Chang 張大慈

CSO, Jellox Biotech Inc.

Andrew H.-J. Wang 王惠鈞

Academician,
Academia Sinica

Sherry Mann-Ching Ku 顧曼芹

Founder & General Manager,
Kuder Consulting Inc.

Day 1 Keynote Speakers

Man-Cheong Fung

President,
Macafex Consulting LLC, USA

Current Position:
- President of MCF Consulting, Inc

Prior Experiences:
- CEO of Tavotek BioTherapeutics, Inc
- Venture Partner, Fidelity Eight Roads Ventures
- Global VP, Johnson and Johnson
- Head of Oncology, Eli Lilly Japan
- Medical Officer, US FDA

Abstract

Contemporary landscape of biotherapeutic discovery is transitioning from the less predictable and somewhat random nature of drug screening to a more disciplined and deterministic paradigm driven by computational design. Traditional antibody discovery has often suffered from many restrictions: poor developability, unexpected immunogenicity, and challenges in targeting structurally complex or undruggable epitopes. These limitations are now being addressed in the modern era, which demands faster speed, better precision, and a higher probability of clinical success.

This presentation reviews the reorientation of the translational process, enabled by the integration of generative AI and high-fidelity digital frameworks. Diffusion models, combined with protein-scale LLMs, are accelerating discovery. Many new antibodies are now carefully designed rather than discovered via the traditional paradigm of serendipity. De novo design also enables the targeting of cryptic epitopes, such as transient conformations in allosteric pockets in oncogenic proteins, which were previously inaccessible to animal-derived repertoires. Through the combination of sequence–structure co-optimization, potential new drug candidates are equipped with better stability, solubility, and manufacturability. Equally revolutionary is the convergence of generative AI with precision medicine, replacing the conventional "one-size-fits-all" approach with a more customized, data-driven personalized strategy through Digital Twins and in silico immuno-profiling. Thereby, customized antibodies can now undergo rigorous virtual screening across diverse patient populations, simulating their interactions with varied HLA haplotypes to proactively reduce potential immunogenicity risks and pharmacokinetic variability. Furthermore, the integration of robotic platforms with predictive CMC analytics also reduces development timelines from years to months while enabling closed-loop optimization between design and manufacturing. By establishing efficacy, safety, and manufacturability as key principles from the initial design, the next generation of biologics allows faster entry into the clinic with a higher chance of success. Collectively, these advancements signify a new path toward the future of rational, in silico-guided biotherapeutic discovery. This strategic convergence of AI, automation, and biological insight is driving a new paradigm in antibody development.

Day 1 Keynote Speakers

Ken J. Ishii 石井健

Professor and Director,
Vaccine Science Division, Institute of Medical Science,
The University of Tokyo

Dr. Ken Ishii is currently Vice Director for UTOPIA(The University of Tokyo Pandemic Preparedness, Infection and Advanced Research Center), Director for International Vaccine Design Center, and Professor of Vaccine Science Division at Institute of Medical Science, University of Tokyo. Until 2018, he was Director of Center for Vaccine and Adjuvant Research at National Institute of Biomedical Innovation, Health and Nutrition. Prof. Ishii obtained M.D. and a Ph.D. from the School of Medicine, Yokohama City University, Kanagawa, Japan. He is further qualified with his years of experience in vaccine research supported by numerous books and over 300 periodical publications whose citations are over 40,000 citations with h-index 91, since 1998 including 7 years as a IND reviewer at US Food and Drug Administration (FDA), two years as Managing Director at Japan Agency for Medical Research and Development (AMED), and over 30 years as an immunologist and vaccinologist.

Abstract

During the COVID-19 pandemic, Strategy for Strengthening the Vaccine Development and Production System, the Strategic Center of Biomedical Advanced Vaccine Research and Development for Preparedness and Response (SCARDA) was established at AMED in March 2022 in Japan, to strengthen strategic research funding and to promote the formation of world-class research and development centers. Together with other 4 universities and supporting institutions, The UTOPIA Center in the University of Tokyo, is dedicated to pandemic preparedness, infection control, and advanced research in medical sciences, aligning with global objectives like the G7's "100 Days Mission" with CEPI to respond quickly to future pandemic threats.

This presentation likely covers the progress, strategies, and innovations in vaccine technology aimed at rapid deployment during health crises, contributing to global efforts in disease prevention and management, as well as the introduction of some innovative research and development for vaccines and the related science and technologies. In particular, extracellular vesicle (EV)-targeting DNA/RNA vaccine and unique small compounds modulating cGAS-STING and ZBP1,by a single nano-particle based technology, database-driven, AI-assisted screening and design for vaccine/adjuvant R&D are of our particular interest. We also spend some efforts on outreaching from children to students to politicians to anti-vaxxers for vaccine confidence and acceptance.

Lab HP; https://vaccine-science.ims.u-tokyo.ac.jp/en/
HP for vDESC; https://vdesc.ims.u-tokyo.ac.jp/en/
HP for UTOPIA; https://en.utopia.u-tokyo.ac.jp/.

Day 1 Keynote Speakers

Alice L. Yu 陳鈴津

Distinguished Chair Professor,
Institute of Stem Cell & Translational Cancer Research in Chang Gung Memorial Hospital Academician, Academia Sinica

Alice L. Yu, M.D., Ph.D. is an Academician of Academia Sinica in Taiwan, currently a Distinguished Chair Professor at the Institute of Stem Cell & Translational Cancer Research in Chang Gung Memorial Hospital & Professor Emeritus of Pediatrics at the University of California in San Diego (UCSD). Previously, she was the Chief and Professor of Pediatric Hematology Oncology at UCSD. She obtained MD from National Taiwan University, PhD in Microbiology and Immunology from University of Chicago.

Dr. Yu is a pioneer in developing anti-GD2 mAb (Dinutuximab), culminating in its FDA approval for the treatment of high-risk neuroblastoma in 2015. This marks the first immunotherapeutic agent targeting a glycolipid antigen. Treatment with anti-GD2 has since become standard of care for high risk neuroblastoma. She received Pediatric Oncology Award from the American Society of Clinical Oncology (ASCO) in 2020 and Lifetime Achievement Award from the Advances in zNeuroblastoma Research Association in 2025.

Abstract

Since the approval of the first anti-cancer monoclonal antibody, rituximab, 29 years ago, the number of validated targets for cancer immunotherapies has grown slowly—only about 31 to date. My long-term work has focused on expanding that repertoire. The 2015 approval of dinutuximab, which targets the tumor-associated glycan GD2 for high-risk neuroblastoma, was a milestone: it demonstrated that glycan antigens can be druggable and broadened the universe of exploitable targets. Globo H ceramide, the most prevalent glycan in adenocarcinomas, is an especially promising candidate. Its expression correlates with poorer patient outcomes, it promotes angiogenesis by binding TRAX and releasing PLCβ1 to trigger Ca2+ mobilization, and it functions as an immune checkpoint via activation of the A2A receptor–cAMP–PKA pathway. Beyond tumor-associated glycans, we have pursued multiple discovery strategies—phage-display peptide libraries, glycoproteomic profiling of human embryonic stem cells, and comparative phosphoproteomics of cancer stem cells versus non–stem cells. These approaches have identified three novel targets now being developed as antibody–drug conjugates, with encouraging early results.

Day 1 Speakers

Shie-Liang Hsieh 謝世良

Distinguished Investigator and Director,
Immunology Research Center,
National Health Research Institutes

Education:

National Yang Ming Chiao Tung University (NYCU), Taiwan	Bachelor of Medicine, 1984
National Yang Ming Chiao Tung University (NYCU), Taiwan	Master, Microbiology & Immunology, 1988
University of Oxford, UK	D. Phil. Biochemistry, 1992

Experience:

Stanford University, USA	Post-doctoral fellow	1993/01-1994/02
Immunology Research Center NYCU, Taiwan	Director	2000/08-2010/07
Immunology Research Center Taipei Veterans General Hospital, Taiwan	Director	2005/08-2013/07
Depart. Medical Research Taipei City Hospital, Taiwan	Director	2004/08-2005/01
Institute of Microbiology and Immunology Institute, NCYU, Taiwan	Director	2005/08-2007/07
Institute of Clinical Medicine, NCYU, Taiwan	Director	2010/08-2013/07
Academia Sinica, Taiwan	Distinguished Professor	2004/08-2024/07
Institute of Microbiology and Immunology Institute, NCYU, Taiwan	Joint Appointment Professor	2007/08-present
Institute of Clinical Medicine, NCYU, Taiwan	Joint Appointment Professor	2013/08-present

Abstract

Chronic hepatitis B (CHB) patients fail to produce neutralizing anti-HBs antibodies despite generating antibodies to HBV core antigen, reflecting profound immune dysfunction that limits prospects for immunological recovery. Here we investigate whether CD33, a sialic acid-binding immune checkpoint aberrantly expressed on myeloid cells and lymphocytes in CHB, contributes to this dysfunction. Ex vivo CD33 blockade on peripheral blood mononuclear cells from 65 CHB patients (including treatment-naïve and off-treatment individuals) restored HBsAb production in 38.5% of individuals meeting pre-specified response criteria, and expanded HBV-specific $CD8^+$ T cells recognizing polymerase and surface antigens. Single-cell transcriptomics reveals that CHB patients harbor dysfunctional atypical memory B cells exhibiting aberrant myeloid gene expression and suppressed immunoglobulin synthesis. CD33 blockade reverses these defects, suppressing interferon-stimulated genes while restoring B-cell identity programs and germinal center pathways. High baseline HBV DNA, HBsAg levels, and $CD19^+CD33^+$ frequencies associate with therapeutic response. These findings identify CD33 as a potential immune checkpoint that contributes to adaptive immune dysfunction in CHB and provide a mechanistic rationale for clinical investigation of CD33-directed immunotherapy.

Day 1 Speakers

Kai-Chien Yang 楊鎧鍵

Chair and Distinguished Professor,
Graduate Institute and Department of Pharmacology,
National Taiwan University

Education:

- M.D. National Taiwan University College of Medicine (2000)
- Ph.D. Washington University in St Louis, MO, USA (2012, Molecular Genetics & Genomics)

Current position:

- 2025 Aug- Chair and Distinguished Professor, Graduate Institute and Department of Pharmacology, National Taiwan University (NTU)
- 2020 Aug- Joint Associate Research Fellow, Institute of Biomedical Sciences, Academia Sinica
- 2014 Nov- Attending Physician, Division of Cardiology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan

Relevant experience:

- 2022-2025 Professor, Graduate Institute and Department of Pharmacology, NTU
- 2019-2022 Associate Professor, Graduate Institute and Department of Pharmacology, NTU
- 2014-2019 Assistant Professor, Graduate Institute and Department of Pharmacology, NTU
- 2012-2014 Post-Doc research fellow, University of Illinois at Chicago & Brown University, USA
- 2005-2007 Attending Physician, Division of Cardiology, Department of Internal Medicine, E-Da Hospital, Kaohsiung, Taiwan
- 2000-2005 Resident and clinical fellow in cardiology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan

Fields of specialty:

- Cardiac and organ fibrosis, non-coding RNA biology, cardiac regeneration

Abstract

Fibrosis-related disorders account for an enormous burden of disease-associated morbidity and mortality worldwide. Fibrosis is defined by excessive extracellular matrix deposition at fibrotic foci in the organ tissue following injury, resulting in abnormal architecture, impaired function and ultimately, organ failure. To date, there lacks effective pharmacological therapy to target fibrosis per se, highlighting the urgent need to identify novel drug targets against organ fibrosis. Recently, we have discovered the critical role of a fibroblasts-enriched endoplasmic reticulum protein disulfide isomerase (PDI), thioredoxin domain containing 5 (TXNDC5), in cardiac, pulmonary, renal and liver fibrosis, showing TXNDC5 is required for the activation of fibrogenic transforming growth factor-β signaling cascades depending on its catalytic activity as a PDI. Moreover, deletion of TXNDC5 in fibroblasts ameliorates organ fibrosis and preserves organ function by inhibiting myofibroblasts activation, proliferation and extracellular matrix production. We have also demonstrated that TXNDC5 is also involved in the pathogenesis of tumor desmoplasia and progression. In this presentation, I will detail the molecular and cellular mechanisms by which TXNDC5 promotes fibrogenesis in various tissue types and tumors and will summarize potential therapeutic strategies targeting TXNDC5 to treat organ fibrosis and solid tumors.

Day 1 Speakers

Divay Bagga

Global Product Excellence Manager,
Cell Line Development (CLD), Sartorius

Divay Bagga is a seasoned industry professional specializing in Cell Line Development services for the biopharmaceutical industry. Over two decades, he has built a strong track record of bridging science with business and helping biopharma clients access reliable cell line development, media solutions, and scalable processes to accelerate their drug discovery and development pipelines. With deep domain knowledge in mammalian cell line strategies and early-stage biologics, his work focuses on CHO-based expression systems, stable cell line generation, media optimization, and the development of scalable upstream processes to support biologics manufacturing. Divay is particularly engaged in advancing next-generation CLD platforms that integrate process intensification principles and data-driven clone evaluation to enhance efficiency, reproducibility, and scalability in biologics manufacturing.

With a foundation in Microbiology and Management, he brings a technically grounded and structured perspective to the development of robust cell line platforms for therapeutic protein production.

Abstract

Cell Line Development is rapidly evolving to meet the growing demand for efficient and scalable biologics production. To meet these requirements innovative technologies and data-driven workflows are applied to identify and select high-producing, stable and clonal cell lines that are scalable as early as possible. Some of the advance technologies and strategies used in cell line development include novel genetically engineered CHO host cell lines, automation and AI/ML predictive modelling during clone selection, and high throughput screening tools for clone evaluation both in fed-batch and intensified processes. In this presentation, we will expand on these technologies further and how these approaches create a faster, smarter, and more robust CLD process that ensures success to biopharmaceutical development.

Day 1 Speakers

Pei-Jiun Chen 陳佩君

CEO & president,
Mycenax Biotech

Dr. Pei-Chun Chen is a distinguished biopharmaceutical leader with over two decades of experience in development and manufacturing.

In 2009, she joined TPG Biologics, leading advancements in bioprocess technologies and positioning the company as a premier service provider in cell line and process development. Under her leadership, TPG achieved strong international growth, with over 80% of revenue derived from global clients, particularly in Japan.

Following TPG's merger with Mycenax Biotech in 2019, Dr. Chen became CEO and President of the combined company, transforming it into a technology-driven CDMO that integrates biopharmaceutical development with commercial-scale GMP manufacturing. Mycenax has successfully passed rigorous audits by global regulatory agencies, including the EMA, PMDA, and Health Canada, reinforcing its reputation as a trusted partner in biopharmaceutical development and manufacturing. She has also led expansion into advanced modalities such as ADCs and cell therapy, secured capital investments from domestic and international investors, and facilitated a strategic alliance with a leading Japanese pharmaceutical companies, forming a joint venture that expanded Mycenax's footprint in Japan.

Earlier in her career, Dr. Chen contributed to the development of novel antibody therapeutics at AbGenomics Corporation (now AltruBio Inc.). She earned her B.S. in Zoology from National Taiwan University, her Ph.D. in Biology from the University of Michigan, and conducted postdoctoral research at Stanford University and the University of Lausanne.

Abstract

Antibody therapeutics are rapidly evolving beyond conventional monoclonal antibodies toward more complex modalities such as bispecific antibodies and antibody-drug conjugates (ADCs). While these next-generation formats offer greater therapeutic potential, they also introduce increased development complexity.

This presentation will explore why complex biologics require a concept-to-clinical development strategy from the outset. Using bispecifics and ADCs as examples, the talk will examine how molecular complexity is reshaping development requirements across design, manufacturability, and CMC strategy.

It will also provide practical insights into the capabilities, development frameworks, and partnership models needed to successfully translate next-generation antibody innovation into clinical advancement.

SARTORIUS

Octet R8e 分子交互作用分析系統

全新第五代機種

384 well plate OK

- 生物膜干涉技術 (BioLayer Interferometry)，減少樣品前處理步驟及昂貴實驗成本限制
- 多樣化感測探針設計，樣品間完全獨立分析不干擾
- 使用 96/384 孔盤上樣，配合感測探針即時樣品偵測，分析量更大更快速
- 更高靈敏度，適合小分子結合試驗分析
- 有效生物分子濃度定量，以及結合常數親和力偵測分析
- 無任何流體管路，無需任何清洗步驟，樣品絕對不殘留，儀器完全不阻塞
- 無需任何設定動作，樣品即可完全回收不浪費，可進行重複測試或接續其他實驗
- 符合 GxP 需求

多種應用

偵測分子親合力、抗體濃度、HCP、Residual Protein A 等各項功能不變

滿足不同實驗需求

無縫接軌



基礎研究到工業生產，從培養液、粗萃液到純化樣品，皆可使用

可選擇符合 GxP 規範套組

原地升級*

2、4 通道機型可依據日後實驗需求，直接原地升級至 4 或 8 通道

節省時間與經費

大量樣品*

16、96 通道機型可外接自動化設備，實現無人守值自動化上樣分析

高通量連續試驗

R2、R4、R8 及 R8e 機型

分別擁有 2、4 及 8 個獨立檢測通道，高靈敏度及可升級檢測通道設計*，符合您各種不同目的與階段性需求。

RH16 及 RH96 機型

分別擁有最高 16 及 96 個獨立檢測通道，可使用 96 或 384 孔盤進行分析，單次更多的分析樣品數及更低的樣品使用量，讓您在製程開發上，擁有更高的競爭力。

	Octet® R2	Octet® R4	Octet® R8	NEW Octet® R8e	Octet® RH16	Octet® RH96
最大通道數	2	4	8	8	16	96
偵測器	2	4	8	8	16	16
實驗溫度	15 – 40℃	15 – 40℃	15 – 40℃	15 – 40℃	室溫 – 40℃	室溫 – 40℃
樣品盤型式	1 (96 孔盤)	1 (96 孔盤)	1 (96 孔盤)	1 (96 或 384 孔盤)	2 (96 或 384 孔盤)	2 (96 或 384 孔盤)
原地升級	至 R4, R8	至 R8	–	–	–	–
符合 GxP 需求	–	–	O	O	O	O

* 部分規格依不同 Octet 機型而有所差異

SARTORIUS

Modernizing Cell Line Development: Data-Driven Strategies for Biopharmaceutical Success



Speaker:

Divay Bagga

Global Product Excellence Manager, Cell Line Development, APAC

Let's Accelerate Your Biologics Journey Together

Discover the future of biologics with advanced Cell Line Development! Explore how engineered CHO cells, automation, and AI/ML-driven clone selection revolutionize production. Dive into rapid, efficient evaluation with high throughput screening. Join us to see these innovations drive faster, smarter CLD processes for success!

- Completed ~300 CLD projects
- High Versatility (IgG1, IgG2, IgG4, Fc-Fusion, Bi-specifics and complex protein)
- Clinical Track Record 10 Market Approval
- Proven Regulatory Compliant

For more cell line development information, please contact: *apac_sds_asia@sartorius.com*

TargetMol®
YOUR TARGET MOLECULES

一站式服務：

以演算法加速分子預測與新藥開發

From Ligand- and Target-Based Prediction to Drug Discovery – All in One Platform

2023 AWARDS
CiteAb
Data Accelerating Science
BIOCHEMICAL SUPPLIER TO WATCH IN 2023
TargetMol

從 In Silico 到 In Vitro，一次到位!

1. 專屬 AI 平台支援 高通量藥物篩選
2. 800+精選化合物庫，分類明確、資訊齊全
3. 深厚的 CADD 藥物設計實務經驗
4. 具備客製化設計與製備能力

小分子藥物研發三大服務

A	電腦輔助藥物篩選 (Computer-Aided Drug Design-CADD) 1. 虛擬篩選 Virtual Screening 2. 分子對接 Molecular Docking 3. 分子動力學模擬 Molecular Dynamics Simulation 4. 靶點預測 Target Fishing
B	AI智慧導入藥物篩選 (AI-Driven Drug Discovery-AIDD)
C	先導化合物的結構優化 (Structural Optimization of Lead Compounds)

小分子藥物虛擬篩選流程



更多資訊請參考

Omics Bio 盟基生物科技
Web: www.omicsbio.com.tw
Mail: info@omicsbio.com
免付費電話: 0800-222-082

台北總公司
T：02-8698-2268
F：02-8698-2228

高雄分公司
T：07-223-6080
F：07-223-8205

官網 ID：@omicsbio

TWIST BIOSCIENCE × ABreal Biotech Co., Ltd. 倍思特生物科技

數據領航 ✦ 驅動未來
高通量技術重塑次世代生物藥研發藍圖

Scaling Machine Learning in Biologics
Leveraging High-Throughput Data for Next-Gen Biotherapeutic Discovery

Jay Yang

Senior Director, Business Development ,
DNA Synthesis and Protein Solutions ,
Twist Bioscience

2026.5.26
午餐演講

TWIST BIOSCIENCE

釋放高通量抗體生產力：革命性技術，為您的研發全面加速！

✦ 從完美基因到高品質抗體：利用 NGS 驗證序列，實現高通量、高產率的抗體生產!

Twist's platform is designed to provide robust expression of antibody candidates with yields generated for potential antibody hits against a specific antigen **(A)**. Twist expresses antibodies with a >90% success rate benchmarked against a minimum threshold control yield of 100 ug (~0.5 mg/mL) during the production process **(B)**.

✦ 領先業界的 SPR 檢測系統：以卓越數據品質，為您的研發決策提供精準導航。

Twist employs a multi-faceted approach to selecting the most robust and diverse antibody candidates for further development using antibody titer **(B)** affinity ranking **(C)**, sequence diversity, and a variety of affinity ranges shown in our isoaffinity chart **(D)**.

A. 1mL EXPRESSION ANTIBODY YIELD, N=482



B. ANTIBODY TITER, N=482



C. AFFINITY OVERVIEW, Kd (M)



D. ISOAFFINITY CHART (Ka VS Kd)



ABreal Biotech Co., Ltd. 倍思特生物科技
TEL 02-26971322
FAX 02-26971331
www.abrealbiotech.com

ACCELERATE YOUR BASIC RESEARCH

你的專屬客服 ID: @abreal
LINE

gator

Your Trusted Solution for

Antibody Drug Discovery and Development

Gator Pivot System 16x Channels
Label-Free Analysis with Sample Cooling

Experience Next-Gen Biolayer Interferometry

Target Validation

Target Receptor Function

Hit Generation

mAb Affinity Screening

Epitope Binning

Lead Characterization

Binding Kinetics

Epitope Binning

Target Specificity

Lead Optimization

Affinity Maturation

Fc Engineering

Humanization

Fc-Receptor Function

Bioprocessing

Cell Line Development

Process Development

Product Characterization

Potency Assay

For more information on Biolayer Interferometry (BLI) or to request a product demo, please visit gatorbio.com

info@gatorbio.com
linkedin.com/company/gatorbio

Moderator

Yan-Hwa Wu Lee 吳妍華

Academician,
Academia Sinica

Yau-Huei Wei 魏耀揮

Director, Center for Mitochondrial Medicine and Free Radical Research, Changhua Christian Hospital (CCH)

Day 2 Speakers

Chien-Jen Chen 陳建仁

Academician/Distinguished Research Fellow,
Genomics Research Center, Academia Sinica

- Distinguished Research Fellow, Academia Sinica (2006-now)
- Premier, Executive Yuan, Republic of China (Taiwan) (2023-2024)
- Vice President, Republic of China (Taiwan) (2016-2020)
- Vice President, Academia Sinica (2011-2015)
- Minister, National Science Council, Taiwan (2006-2008)
- Minister, Department of Health, Taiwan (2003-2005)
- Dean, College of Public Health, National Taiwan University (1999-2002)
- Director, Institute of Epidemiology, National Taiwan University (1994-1997)
- Director, Institute of Public Health, National Taiwan University (1994-1997)
- Professor, National Taiwan University (1986-2015)

Abstract

The mortality from liver cancer and cirrhosis in Taiwan ranked among the highest in the world in 1980. Liver cancer remained the leading cause of cancer death in Taiwan in early 2000s. The community-based REVEAL HBV/HCV Study has identified significant long-term risk predictors for HCC and cirrhosis in chronic hepatitis B and C patients. Nomograms (risk prediction models) were developed and validated for the personalized prediction of HCC and cirrhosis risk. These nomograms had very good performance in discrimination and calibration capabilities. In order to validate the applicability of risk prediction models in East Asia, an international collaborative group had developed and validated the REACH-B Risk Estimator. An updated REACH-B score was further derived for non-cirrhotic chronic hepatitis B patients. Based on the risk stratification, the National Antiviral Therapy Program for patients with chronic viral hepatitis was launched in Taiwan in 2003. Only chronic viral hepatitis patients with high risk of developing cirrhosis and HCC were reimbursed for antiviral therapy in 2003. After 2009, patients with moderate to high risk were reimbursed for more potent antiviral agents. Direct antiviral agent (DAA) was reimbursed for all HCV RNA-seropositive patients with chronic hepatitis C since 2017. There has been a significant reduction in mortality and incidence of HCC and cirrhosis since 2003. The precision liver disease prevention is cost-effective zto reduce burden of cirrhosis and HCC in Taiwan.

Day 2 Speakers

Wen-Hwa Lee 李文華

Academician/Visiting Distinguished Chair Research Fellow,
Academia Sinica

Abstract

Pancreatic ductal adenocarcinoma (PDAC) accounts for 95% of all pancreatic cancers and is one of the most lethal diseases despite marked improvement in medical and cancer care over the past forty years. More than 80% of PDAC patients are diagnosed with advanced stages of the disease when cancer cells have already spread. Less than 20% of patients have a surgically removable disease; however, 80% of patients will relapse following surgery and eventually die of metastasis.

In this talk, I plan to discuss the first step of how PDAC initiates and how the tumor cells metastasize to distant organ.

KRAS mutations are the earliest events found in approximately 90% of PDACs. However, little is known as to why KRAS mutations preferentially occur in PDACs and what processes/factors generate these mutations. We showed that under high-glucose conditions, cellular O-GlcNAcylation is significantly elevated in pancreatic cells that exhibit lower phosphofructokinase (PFK) activity than other cell types. This post-translational modification specifically compromises ribonucleotide reductase (RNR) activities leading to imbalance of dNTP pools, genomic DNA alterations with KRAS mutations, and transformation of cells. These results provide a mechanistic view of how perturbed sugar metabolism triggers genomic instability and initiates de novo oncogenic KRAS mutations preferentially in pancreatic cells. Nevertheless, mutated KRAS alone is insufficient to initiate pancreatic intraepithelial neoplasia (PanIN), the precursor of PDAC. We then use optic-clear 3D histology to analyze entire pancreases of 2-week-old Pdx1-Cre; LSL-KrasG12D/+ (KC) mice to detect the earliest emergence of PanIN and observed that the occurrence is independent of physical location. Instead, we found that the earliest PanINs through genomic alterations, overexpress Muc4 to increase proliferation and fibroblast recruitments via Activin A secretion and consequently enhance cell transformation for PanIN formation. These findings emphasize the vital role of interactions between oncogenic KrasG12D/+-driven genetic alterations and induced microenvironmental changes in PanIN initiation.

The development of life-threatening metastasis at distant organs requires at least two key steps. The first is that tumor cells leave the primary site, entering and surviving in circulating blood. The second is the disseminated tumor cells adapt to, and co-evolute with, the drastically different microenvironments of metastatic sites. It was noted that circulating tumor microemboli (CTM), which are likely to be responsible for the seeding and dissemination of cancer, originate from the primary tumor mass and spread to the peripheral circulation and its amount correlates with worse progression in clinical setting. Interestingly, PDAC is characterized by extensive desmoplasia with fibroblasts as the major cell type. Direct cell-cell contacts forming heterocellular aggregates between fibroblasts and tumor cells were detected in primary pancreatic tumors and circulating tumor microemboli (CTM). Mechanistically, the overexpressed ATP1A1 of tumor cells binds to and reorganizes ATP1A1 of fibroblasts inducing calcium oscillations, NF-κB activation, and activin A secretion to facilitate tumor invasion and colonization. Finally, how CTM adapt at the metastasis sites is of importance to explore and will be discussed.

Day 2 Speakers

Hsing-Jien Kung 龔行健

Chair Professor,
Taipei Medical University, Taiwan

EDUCATION:

- 1965-69 B.S. Chemistry, National Taiwan University
- 1970-75 Ph.D. Chemistry, California Institute of Technology

RESEARCH AND PROFESSIONAL EXPERIENCE:

- 1976-78 Postdoc, Microbiology, UC San Francisco
- 1978-1982 Assistant Professor, Department of Biochemistry, Michigan State University
- 1982-June 1984 Associate Professor, Department of Biochemistry, Michigan State University
- June 1984-July 1988 Associate Professor, Dept. of Molecular Biology & Microbiology, CWRU School of Medicine
- July 1988-1998 Professor, Dept. of Molecular Biology & Microbiology, CWRU School of Medicine
- 1989-1998 Professor, Department of Medicine, Case Western Reserve University School of Medicine
- 1990-1998 Associate Director of Basic Science, CWRU Cancer Center
- 1998-2012 Professor, Dept. Biochemistry and Molecular Medicine, UC Davis, School of Medicine
- 1998-2018 Deputy Director and Director of Basic Research, UC Davis Cancer Center
- 2008-2018 Distinguished Professor, Dept. Biochemistry and Molecular Medicine, UC Davis, School of Medicine
- 2012-2015 President, National Health Research Institutes, Taiwan

Abstract

We have been interested in exploring EV RNAs associated with muscle aging and sarcopenia as biomarkers. They are also likely biosignatures as the contents of EV often reflect the cellular and disease states. With its exquisite and specific sensitivity, EV RNAs provide a rich source for exploring potential biomarkers and intervention targets, as well illustrated for EV miRNAs and lnc RNAs in previous studies. In the present work, we have focused on EV mRNAs, which, in our view, not only serve as biomarkers but also directly inform the biology of the disease states and potential treatment strategies. Using both targeted and unbiased screen approaches, we have identified EV mRNAs associated with different stages of muscle aging and sarcopenia. Functional studies of proteins encoded by these EV mRNAs shed lights on the mechanisms of muscle aging. Our initial progress will be presented. The work represents a collaboration among TMU, NHRI, NCYU/VGH, UT, with support from NHRI and NSTC.

Day 2 Speakers

Ming-Che Shih 施明哲

Academician,
Academia Sinica

2017 ~ Current, Distinguished Research Fellow and Chair, Academia Sinica Southern Campus Planning Commission

2016 ~ 2017, Distinguished Research Fellow and Secretary General of Academia Sinica

2008 ~ 2016, Distinguished Research Fellow and Director

2003 ~ 2008, Professor, Dept. of Biological Sciences, University of Iowa, USA

2005 ~ 2007, Director, Center for Comparative Genomics, University of Iowa, USA

1994 ~ 2003, Associate Professor, Dept. of Biological Sciences, University of Iowa, USA

1988 ~ 1994, Assistant Professor, Dept. of Biological Sciences, University of Iowa, USA

1984 ~ 1988, Postdoctoral Fellow Dept. of Genetics, Harvard Medical School, USA

1978 ~ 1983, Ph.D. Genetics Ph.D. Program, University of Iowa, USA

Acknowledgement

Thanks for your supporting

Board of Directors

林榮耀 董事長、吳漢忠 董事暨執行長、吳華林 董事、李德章 董事、林世昌 董事、魏耀揮 董事、
余明俊 董事、呂郁蕙 董事、戴明泓 董事、蔡家櫸 助理執行長

Organizers

TAA 社團法人台灣抗體協會 TAIWAN ANTIBODY ASSOCIATION

Co-Organizers

DOB 生物技術開發中心 Development Center for Biotechnology

NBRP National Biotechnology Research Park 國家生技研究園區

BioMReC 生醫轉譯研究中心 Biomedical Translation Research Center

NCB 國家實驗研究院 國家生物模式中心 National Center for Biomodels

臺灣臨床前試驗聯盟 TCROSS Taiwan Contract Research One-Stop Service

Co-Organizers

UNIMED 騰達行

SARTORIUS

Omics Bio 盟基生物科技股份有限公司

ABreal Biotech Co., Ltd. 倍思特生物科技

gator

BIOINTRON

Supporting Organizers

MOLECULAR DEVICES

均泰生物科技股份有限公司 Genetech Biotech Co., Ltd.

伯森生技

Waters | TA Instruments

岑祥

PharmaEssentia

BECKMAN COULTER Life Sciences

EirGenix

cytiva

Sponsors

BD

MYCENAX 永昕生醫

nuclera

從 DNA 到 Protein 只要 2 天

eProtein Discovery System

高通量蛋白表達篩選系統

經驗證的性能

90% 蛋白質可獲得率

92% 平均純度

超過 **1000** 種 蛋白質成功表達

平均產量 **146 µg / mL**

66% 人類蛋白質

Step 1: Design

Design, order and prepare DNA constructs



AI-guided variant design with optional solubility tags

Automatic codon optimization and compatibility checks

Select between linear or circular DNA

Generate expression-ready DNA using eGene™ Prep Kits, or order ready-to-use DNA

Step 2: Express & Purify

Automated digital microfluidics screen to determine your path to soluble, purifiable proteins



Select between our Soluble or Membrane protein workflow

> Soluble Protein Workflow

24 (eGene™) × 8 (Customizable Cell-free Blends) = 192 (Expression data points)

30 Purification data points of the highest expressors

> Membrane Protein Workflow

11 (eGene™) × 8 (Customizable Cell-free Blends) = 88 (Expression data points)

88 Purification data points

Total time: < 48 hours to µg of protein (Hands on time < 2 hours)

Step 3: Scale-Up

Scale-up proteins at µg- and mg-scale

Choose best construct/Cell-free blend combination to scale up overnight

µL-mL options available

µg–mg of purified protein ideal for cryo-EM, functional assays, and more

The CytoFLEX Platform:

10 Years of Transforming Science

www.beckman.com/flow-cytometry

美商貝克曼庫爾特有限公司台灣分公司生命科學部

台北市106敦化南路二段216號8樓
聯繫郵箱: lstaiwan@beckman.com

售後維修專線:0800-211-283
產品諮詢熱線:0800-212-134

BECKMAN COULTER
Life Sciences

MOLECULAR DEVICES

LEARN MORE

SpectraMax® iD5e

多模式微量盤讀取儀

強化複雜檢測的應用能力

SpectraMax® iD5e 進化型微量盤讀取儀專為突破檢測極限的您而全新打造。結合靈活及靈敏的Hybrid光學系統、5+N種偵測模式，並支援TR-FRET、HTRF®、螢光偏振與Western blot檢測，最大程度滿足生醫科學，藥物開發的需求。現更搭配Aer環境控制及進階震盪功能、將啟用長時間穩定、有效的動態觀測需求。SoftMax® Pro 專業版軟體將從擷取、分析、統計、制圖的端到端資料處理方案，為您的團隊提供一站式的卓越效能。

聯絡我們

電話：+1.800.635.5577
網站：www.moleculardevices.com
電郵：info@moldev.com

各地區辦事處

美加	+1.800.635.5577	台港澳	+886.2.2656.7585
英國	+44.118.944.8000	日本	+81.3.6362.9109
歐洲*	00800.665.32860	南韓	+82.2.3471.9531
中國	+86.4008203586	印度	+1.800.266.5338

*奧地利、比利時、丹麥、芬蘭、法國、德國、冰島、愛爾蘭、義大利、盧森堡、荷蘭，葡萄牙、西班牙、瑞典、瑞士及英國

danaher

cytiva

In vivo CAR-T platforms that take you from concept to manufacturing

Guide for Cytiva tLNP solutions

Selected for a major program by ARPA-H,
Cytiva is advancing non-viral, LNP-based in vivo CAR-T therapies, bringing cell therapy closer to a simple, scalable treatment model.

We provide integrated solutions across development stages, supporting process optimization, scale-up, and manufacturing readiness, helping you move efficiently from innovation to clinical translation.

Our tLNP platform is designed to deliver robust, reproducible, and scalable processes, ensuring consistent performance and enabling real-world application.

Why Cytiva

- **End-to-end solutions from design to manufacturing**
- **Scalable from research to GMP production**
- **Built for mRNA, CRISPR, and in vivo applications**
- **Accelerating the path from concept to clinic**



"Innovation only matters when it can be manufactured."

cytiva.com

V(D)JC 完整定序，全面解析 TCR/BCR 免疫組庫資訊

iRepertoire
免疫組庫完全解析方案



應用範圍

- 免疫細胞族群變異分析
- 個體免疫年齡評估
- 抗體藥物研究
- 癌症免疫療法開發
- 疾病狀態評估與伴隨診斷

專利 arm-PCR 技術

- 7 種 TCR/BCR 序列完整分析
- 客製化多鏈組合
- 視覺化免疫組庫圖譜

均泰生物科技股份有限公司
Genetech Biotech Co., Ltd.

台北市內湖區新湖二路168號4樓
E-mail sales@gtbiotech.com.tw
TEL +886-2-27965108
FAX +886-2-27965907

iRepertoire

iLite® 冷光細胞平台

抗體 / 雙特異性抗體效能驗證首選

ADCC | ADCP | CDC | Bispecific | T-cell Engager

iLite® Cell-based Assays

SVAR

iLite® 冷光細胞可將 ADCC、ADCP、CDC 及雙特異性抗體/ T 細胞抗體 (bsAb/TCE) 接合等抗體藥物效能，轉化成冷光訊號分析，加速藥效與標靶專一性驗證。

品項齊全

提供各類效能驗證的
Effector 與 Target Cell。

即開即用

解凍即測。
免除細胞培養
耗時與操作誤差。

精準數據

雙冷光系統，
可標準化實驗結果，
避免細胞數量不同
所造成的變異



欲了解產品詳情，歡迎蒞臨伯森生技攤位，或洽詢伯森生技業務專員。

伯森生技
www.blossombio.com
(北部) 0800-059668 (南部) 0800-259988

NATIVE BIOTHERAPEUTIC CHARACTERIZATION

NO LABELING or SAMPLE IMMOBILIZATION

Accurate
Sensitive
Reproducible

Binding Affinity. Structure Stability. Enzyme Kinetics.

TAInstruments-TA儀器
美商沃特斯國際股份有限公司台灣分公司
TEL: +886-2-25638880
Email: TA_Taiwan@waters.com

Waters™ | TA™ Instruments

tainstruments.com

GenScript
Scripting Possibilities

TurboCHO™
為極速而生

序列一交，抗體到手！

更快速　更靈活　更可靠

- 無需自行建構，一站完成
- 高效表達系統，大幅縮短時程
- 支援多種抗體格式（mAb / Fab / scFv / bispecific）
- 研究級到應用級，一次到位

掃描看更多

PORTAL

分子機械遞送系統

slas NEW PRODUCT AWARD

一次搞定多種細胞與分子！

突破細胞遞送極限！開啟新一代藥物篩選與開發可能性

支援多元分子遞送

mRNA、siRNA、saRNA、蛋白質、胜肽、抗體
奈米顆粒、CRISPR RNP

廣泛適用細胞系統

iPSC、T 細胞、HEK 細胞
涵蓋多種難轉染細胞

遞送分子，就是這麼簡單！

掃描看更多

騰達行 UNIMED
0800-211-819
Unimed 騰達行
www.unimed.com.tw
台北 02-2720-2215　新竹 03-6684-586　台中 04-2463-3591　嘉義 05-2844-162　台南 06-2890-665　高雄 07-3470-143　花蓮 03-8573-757

EirGenix

TAIWAN'S LARGEST CDMO FOR BIOLOGICS

ONE-STOP SHOP CLINICAL & COMMERCIAL

- Mono & Bi & Poly-specific Antibodies
- Antibody Drug Conjugates (ADCs)
- Recombinant Proteins & Peptides
- Plasmid DNAs (pDNAs)
- Biosimilars
- Vaccines

Since 2012

1.0 Bn USD
Market Capitalization

90+
Products

29.6 kL
Total Capacity (& Growing!)

15+
Countries for IND/NDA Sub.

CELL LINE DEVELOPMENT

- Mammalian & Microbial

PROCESS DEVELOPMENT

- Upstream & Downstream & Formulation

ANALYTICAL SERVICES

- Development & Validation & Characterization

GMP MANUFACTURING

Mammalian
2 x 200L, 5 x 1,000L, 12 x 2,000L SUBs
3 x 15,000 SUBs (2028)

Microbial
1 x 30L, 1 x 150L Fermentors
1 x 75L, 500L, 1 x 1,500L Fermentors (2025)

REGULATORY SUPPORT

Inspections & Approvals

Contact Us : bd@eirgenix.com

US FDA | EU EMA | Japan PMDA | Taiwan FDA | Australia TGA

Manufacturing for Pre-Clinical to Commercial Supply!

ZHUBEI FACILITY (A)
Clinical to Commercial

Mammalian
- 1000 L x 2 SUBs
- 2000 L x 12 SUBs

ZHUBEI FACILITY (B)
Clinical to Commercial

Microbial
- 75 L x 1 Fermentor
- 500 L x 1 Fermentor
- 1500 L x 1 Fermentor

XIZHI FACILITY
Pre-Clinical to Commercial

Mammalian
- 200 L x 2 SUBs
- 1000 L x 1 SUB

Microbial
- 30 L x 1 Fermentor
- 150 L x 1 Fermentor

QIAOTOU FACILITY
Commercial (Global Scale)

Mammalian
- 15000 L x 10 SSBs

Cost-Effective
High Value-to-Cost Ratio Services

Flexible
Client-Orientated, Customized Service Packages

Timely
Competitive Timelines to Meet Client Targets

High Quality
Internationally-Recognized Quality Services

Experienced
Broad and Extensive CDMO Track Record

掌控醣基化，掌控抗體療效

岑祥為您建立以醣基化為核心的製程控制循環

懸浮型細胞培養

適用各類懸浮型細胞，也適合微載體應用

ABER Futura
電容活細胞感測器

即時監控，反應真實細胞數據

Getinge Applikon
智能生物反應器

以1打2，輕鬆線性放大

貼附型細胞培養

適用各類貼附型細胞，也適合生產
Exosome、病毒以及疫苗

Cytiva iCellis Nano
固定床反應器

以小博大，小體積大產量

所有路徑的共通 PAT 閉環

Nova State Profile® CCS Prime
代謝分析儀

簡單上機，隨時分析

掌控關鍵代謝，
為理想糖基化鋪設完美基石

Solentim ICON™ x PAIA
細胞株開發平台

加速開發效率，一站式分析：

- 四大 Glycan
- 細胞存活率
- IgG titer

極速快篩，
鎖定完美糖型CQA

CHO Host Cell Proteins (HCP) ELISA Kit
- 全面監控HCP，守住生物製劑品質關卡

Glycan Array 100/300
- 更全面的醣體分析，掌握關鍵生物訊號

極速快篩，鎖定完美糖型CQA

PAIA Glycan
高通量醣基化篩選試劑

Alliance with

GETINGE ABER cytiva NOVA BIOMEDICAL RayBiotech

LIFE SCIENCE TECHNOLOGIES
岑祥股份有限公司
台北：02-27851156 新竹：03-5307592 台南：06-2071392
台中：04-24710255 高雄：07-3431735 info@thco.com.tw
官網 LINE@

PharmaEssentia

BESREMi™

(ropeginterferon alfa-2b)

INJECTION

治療不具症狀性脾腫大之成人真性紅血球增多症。

衛部菌疫製字第000143號

藥華醫藥股份有限公司
台北市南港區園區街三號13樓
02-2655-7688
北市衛藥廣字第114120109號

臺灣臨床前試驗聯盟

T.CROSS

Taiwan Contract Research One-Stop Service

台灣臨床前試驗聯盟

Taiwan Contract Research One-Stop Service, T.CROSS

Joint Laboratories' Core Capabilities in In Vivo ADMET

國家實驗研究院 NATIONAL INSTITUTES OF APPLIED RESEARCH

BioMReC 生醫轉譯研究中心 Biomedical Translation Research Center

工業技術研究院 Industrial Technology Research Institute

財團法人生物技術開發中心 Development Center for Biotechnology

國家衛生研究院 National Health Research Institutes

第一階段 先導化合物篩選與優化

- 候選藥物目標產品特徵(Target Profile)建立
- 化合物小規模生產與化學性質研究
- 體內與體外藥效學研究
- 早期藥物動力學與物種選擇研究
- 早期毒理與安全性評估

第二階段 藥物代謝與藥動研究

- 核心 ADMET 與藥物動力學研究
- Non-GLP 毒理與毒代動力學試驗
- CMC生產時程與規劃確認
- 製劑與生物分析方法建立

第三階段 臨床前安全性與IND準備

- 製劑與生物分析方法確效
- 基因毒性試驗
- 安全藥理試驗
- 重複劑量毒性與毒代動力學試驗
- 臨床一期試驗之初步規劃

https://t.cross.org.tw/index.html

info@t.cross.org.tw

BD FACSDiscover™ A8 Cell Analyzer

with BD SpectralFX™ Technology and BD CellView™ Image Technology

卓越的光譜效能 | 即時影像分析功能 | 雙影像模式彈性切換 | 整合式自動上樣裝置 | 操作簡便

體驗流式細胞儀的未來，盡在 BD FACSDiscover™ A8 細胞分析儀。解鎖光譜流式細胞術與即時單細胞影像功能，整合於一套無縫工作流程中。透過 BD SpectralFX™ 技術、雙影像模式、整合式自動進樣裝置與簡化的操作流程，讓您的研究變得更快速、更強大。

新加坡商必帝股份有限公司台灣分公司
台北市信義區忠孝東路四段560號3樓

BD

MYCENAX 永昕生醫

Your CDMO Partner that Offers Integrated Solutions for Biologics

Regulatory Agency Inspections

EMA · PMDA · Health Canada · MFDS · MHRA

Ensuring excellence with proven track record of fulfilling GMP compliance across the globe.

New CDMO: Alfenax Biolgics Corporation

- A joint venture with alfresa · CHIOME · Kidswell Bio
- Expanding footprint in Japan.

※Supported by MHLW subsidy
(Japan's ministry of health, labour and welfare)

ADC Turnkey Solutions

- Strategic alliance with RIN Institute Inc · SPERA PHARMA
- Delivering seamless solutions from bioconjugation design to commercial production.

Proprietary Technology

NaxLEAP™ (Transposon Technology)

Constructing high-yield and highly stable CHO cell clones through innovative transposon technology.

***ExoMX™* (Exosome Platform)**

Integrating 3D microcarrier processes with high-recovery purification to boost EV yield and stability.

MMA Linker™ (Multi-arm Linker)

Boosting potency through higher DAR and dual-payload synergy to overcome drug resistance.

Commercial Production

Drug Substance Manufacturing :
Mammalian : 8,000L +
Microbial : 5L / 50L / 200L

Vial Aseptic Filling & Finishing :
6,000 units / hr (Max Speed)

PFS Aseptic Filling & Finishing :
11,800 units / hr (Max Speed)

Auto-Injector Production :
2,100 units / hr (Max Speed)

Our Services

Mammalian Manufacturing · Microbial Manufacturing · Antibody-Drug Conjugate · Cell & Gene Therapy · Analytics

Memo

2026

ATC抗體藥物暨第21屆前瞻生醫新知研討會

Antibody Therapeutic Conference & 21st Frontiers in Biomedical Sciences Conference

Organizers

TAA 社團法人台灣抗體協會 TAIWAN ANTIBODY ASSOCIATION

Co-Organizers

DOB 生物技術開發中心 Development Center for Biotechnology

NBRP National Biotechnology Research Park 國家生技研究園區

BioMReC 生醫轉譯研究中心 Biomedical Translation Research Center

NCB NARLabs 國家實驗研究院 國家生物模式中心 National Center for Biomodels

臺灣臨床前試驗聯盟 TCROSS Taiwan Contract Research One-Stop Service

Co-Organizers

UNIMED 騰達行

SARTORIUS

Omics Bio 盟基生物科技股份有限公司

ABreal Biotech Co., Ltd. 倍思特生物科技

gator

BIOINTRON

Supporting Organizers

MOLECULAR DEVICES

均泰生物科技股份有限公司 Genetech Biotech Co., Ltd.

伯森生技

Waters | TA Instruments

岑祥

PharmaEssentia

BECKMAN COULTER Life Sciences

SirGenix

cytiva

Sponsors

BD

MYCENAX 永昕生醫